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Abstract
Idiopathic pulmonary fibrosis (IPF) is a complex disease involving various cell types. Macrophages are essential in main-
tenance of physiological homeostasis, wound repair and fibrosis in the lung. Macrophages play a crucial role in repair and 
remodeling by altering their phenotype and secretory pattern in response to injury. The secretome of induced pluripotent 
stem cells (iPSC-cm) attenuates injury and fibrosis in bleomycin injured rat lungs. In the current study, we evaluate the effect 
of iPSC-cm on gene expression and phenotype of interstitial macrophage in bleomycin injured rat lungs in vivo. iPSC-cm 
was intratracheally instilled 7 days after bleomycin induced lung injury and assessed 7 days later and single cell isolation 
was performed. Macrophages were FACS sorted and microarray analysis was performed. We characterized changes in the 
rat lung interstitial macrophages using transcriptional profiling. iPSC-cm reduced the total collagen content of the lung and 
reduced different macrophage populations. Gene set enrichment analysis revealed involvement of three essential pathways 
(a) immune modulation, (b) branching morphogenesis and (c) canonical Wnt signaling. This study demonstrates that iPSC-
cm reduces fibrosis in bleomycin injured rat lung by partially altering the macrophages and regulating their gene expression.
Keyword Lung fibrosis · Macrophages · Induced pluripotent stem cells · Stem cell secretome
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common 
form of idiopathic interstitial pneumonias and is character-
ized by progressive loss of alveolar epithelial integrity due 
to dysregulated wound repair response to repeated alveolar 
microinjuries [1, 2]. Moreover, recruitment and activation 
of myofibroblasts and exaggerated deposition of extracel-
lular matrix and collagen results in loss of parenchymal 
architecture and lung function [3]. IPF is a rapidly pro-
gressive disease [4] with median survival of 3 years [5] 
and is characterized by histopathological pattern of usual 
interstitial pneumonia [6]. Although the exact etiology of 
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IPF is not known, recent evidence suggest a very complex 
and dynamic process involving various cell types including 
macrophages [7].
Macrophages play a very critical role in defense, metab-
olism and maintenance of homeostasis. Macrophages 
demonstrate distinguished plasticity in acquiring pheno-
types that can either promote or resolve fibroprolifera-
tive response to injury. Based on their location, pulmo-
nary macrophages are divided into alveolar macrophages 
(AMs) residing in airways and interstitial macrophages 
(IMs) located in lung parenchymal tissue [8]. Historically, 
the macrophages where described as classically activated 
or M1 and alternatively activated or M2 macrophages. 
Recent advances, however, have changed our understand-
ing of macrophage phenotypes, plasticity and their specific 
role in fibrosis [9]. It is now recommended to classify the 
macrophages based on their secretions rather than surface 
marker expression [9]. Macrophages are crucial regula-
tors of fibrosis and are seen in close proximity to myofi-
broblasts and produce profibrotic mediators. AMs have 
been shown to secrete matrix metalloproteinases [10] and 
uptake collagen [11]. However, the role of IMs is not fully 
known. Based on some murine studies, it is considered 
that they assume a pro fibrotic phenotype [12]. Therefore, 
targeting these cells to resolve fibrosis could be a promis-
ing novel approach.
Currently there is no cure for IPF. Novel approaches like 
stem cell based therapies have been successfully tested in 
animal models over past years, but their safety for clinical 
application is still under investigation [13]. Generation of 
induced pluripotent stem cells (iPSC) by reprogramming 
represents a very promising approach in the field of regen-
erative medicine [14]. However, the fate of iPSC after cell 
transplantation is debated [15]. In our opinion, the iPSC 
secretome (conditioned media) represents advantage over 
cell transplantation. Its effect has been successfully dem-
onstrated by attenuation of fibrosis in bleomycin injured 
rat lungs by secretome of induced pluripotent stem cells 
(iPSC-cm) [16, 17]. However, mechanisms leading to the 
beneficial effect of iPSC-cm are not fully known. To fur-
ther understand the antifibrotic mechanisms of iPSC-cm, in 
the current study we focused on its effect on macrophages. 
We therefore conducted a microarray experiment to inves-
tigate the effect of iPSC-cm on phenotype and gene expres-
sion pattern of interstitial macrophages in the bleomycin 
injured rat lung. We performed Gene Set Enrichment Anal-
ysis (GSEA) to detect which pathways are being affected 
after treatment with iPSC-cm in the macrophages. The 
most significant pathways were then further investigated 
using network analysis techniques to find which genes and 
gene interactions play a crucial role in the observed phe-
notypic changes.
Materials and Methods
Generation of Induced Pluripotent Stem Cells
Human foreskin fibroblasts (line CRL-2429; ATCC, Rock-
ville, MD, USA) were used to generate iPSC as previously 
described [16]. Cells were maintained in KnockOut™ 
DMEM supplemented with 20% KnockOut™ Serum 
Replacement, 2 mmol/l L-Glutamine, 40 µg/ml gentamycin, 
100 µmol/l β-mercaptoethanol (Gibco, NY, USA) and 10 ng/
ml of human fibroblast growth factor-basic (bFGF; Pepro-
Tech, UK). Medium was changed every day to maintain the 
cells undifferentiated. iPSC colonies were mechanically pas-
saged every 4–5 days as described [16]. For characterization 
the iPSC colonies were immunostained with Oct ¾ (1:50), 
NANOG (1:50), Sox-2 (1:50), TRA-1-81 (1:50), TRA-1-60 
(1:50) (Santacruz Biotechnologies, USA).
iPSC‑cm Collection
10–12 iPSC colonies (6.5 ± 0.53 × 105) live cells were grown in 
feeder free condition on plates coated with vitronectin (Stem cell 
technologies, Canada) one day later the medium was switched to 
KnockOut™ DMEM prepared as mentioned above, but without 
serum replacement and bFGF. After 24 h, the supernatant was 
harvested in falcon tubes and the cellar debris removed via cen-
trifugation (300 g x 5 min). The supernatant was aliquoted and 
stored at − 80 °C. To confirm pluripotency after culture in KO 
DMEM media with serum and bFGF the colonies were stained 
with the pluripotency markers as stated above.
Animals
Male Fisher F344 rats (240 to 280 g) were obtained from 
Charles River Laboratories GmbH (Sulzfeld, Germany). Experi-
ments were performed in accordance with the standards of the 
European Convention of Animal Care. The study protocol was 
approved by the University of Bern Animal Study Committee.
Instillation of Bleomycin
At day 0, animals were anesthetized by inhalation of 4% iso-
flurane in anesthesia chamber and intubated with 14G cath-
eter (Insyte, Spain), and instilled with bleomycin (Baxter, 
USA) (1.28 U/rat) in a volume of 500 µl.The dosage of bleo-
mycin was based on previously published experiments [18].
Instillation of iPSC‑cm or Control Media
Seven days after instillation of Bleomycin, rats were anes-
thetized as mentioned above and an intratracheal instilla-
tion of either iPSC-cm (n = 5) or control media (Ko media 
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without serum replacement and bFGF (n = 5) was performed 
in a volume of 500 µl. Additional animals (n = 5) served as 
normal controls. For time course experiments additional ani-
mals were instilled with bleomycin as described and where 
randomly divided into 2 groups (a) iPSC-cm (b) control 
media, and animals were sacrificed at 24 h, 48 h 72 h or 
7 days after instillation of respective media (n = 3) in each 
group for each time point.
Assessment
At day 14 (7 days after iPSC-cm or control media instillation), 
the animals were anesthetized following the same procedure 
as above and euthanized with intraperitoneal administration 
of 50 mg/kg thiopental. The heart–lung block was removed, 
rinsed with PBS and were either frozen at -80 °C for RNA 
isolation or fixed in paraformaldehyde for histology, or were 
directly used for single cell isolation as described below.
Preparation of Cell Suspension
Resected lungs were mechanically minced in a 10 cm Petri 
dish (BD) with surgical scissor and incubated in a sterile 
solution of RPMI 1640 (Gibco,USA) containing 0.1% col-
lagenase I, 0.25% collagenase II (Worthington Biochemi-
cal Corporation, NJ, USA) and 2% FBS (Gibco). The Petri 
dish was incubated at 37 °C and 5%  CO2 for 90 min, every 
15 min the lung undergoing digestion was pipetted up and 
down to help the cells to disaggregate. The cells suspension 
was consecutively strained in 100 µm and 40 µm filters (SPL 
Life Sciences, S.Korea). Cells were then washed with fresh 
RPMI 1640 and centrifuged at 1680 rpm for 15 min at room 
temperature. Red blood cell lysis buffer (eBiosciences, USA) 
was added to the suspensions of cells according to manufac-
turer instructions to eliminate red blood cells. After lysis, the 
cells were washed and kept in PBS with 2% FBS at 4 °C for 
further analysis.
Antibody Labelling and Flow Cytometry (FACS)
A minimum of 1 × 106 cells from the cell suspension were 
rinsed with washing buffer (WB) containing PBS, 0.1% 
BSA (Sigma) and 0.09%  NaN3 (Sigma). Cells were incu-
bated in 100 µl of washing buffer with the appropriate 
antibody cocktail for surface markers for 30 min at 4 °C, 
protected from light. The cells were then permeabilized 
with PBS containing 2% FCS, 1% EDTA 0.5M pH 8.0, 
0.1% saponin and 0.09% NaN3 and further stained with 
the intracellular marker CD68:AF488 (AbD Serotec,USA).
Antibodies were diluted in WB at concentration of 5 µl/
ml AF488 anti-CD68, 3 µl/ml AMCA anti-CD163, 3 µl/
ml APC-Cy7 anti-CD206, 3 µl/ml PE anti-CD86 and 3 µl/
ml AF647 anti-CD11b.
The same amount of cells was used for isotype and fluo-
rescence minus one (FMO) controls. Compensation was 
achieved using OneComp eBeads (eBioscence, San Diego, 
USA) following manufacturer instructions. At least 5 × 105 
events were acquired using LSRII (SORP) flow cytom-
eters (BD Biosciences, USA) and data was analyzed using 
FlowJo software 10 (FlowJo Enterprise, USA).
Sorting of Macrophages
Lungs of rats were prepared for cell suspension following 
the procedure mentioned above using a mix of collagenases. 
The cell suspension was stained with an anti-rat macrophage 
marker PE (Affymetrix, USA cat no.12–0660) and living cell 
marker 7-AAD (7-aminoactinomycin D) (BioLegend,USA). 
Sorting was performed using a FACS Aria III (BD Bio-
sciences, USA). The freshly sorted cells were collected and 
RNA extraction was performed as described below. For 
FACS plot please see supplementary figure (Fig S-1).
Histology and Immunohistochemistry
For immunohistochemistry samples were deparaffinized 
in series of xylene washes and sequentially re-hydrated 
following decreasing concentrations of ethanol. For rou-
tine histology the slides were stained with hematoxylin 
and eosin (H&E) staining. For immunohistochemistry the 
slides were pretreated in sodium citrate buffer (100 mM, 
pH 7.0) and boiled in a microwave oven for 5 mins. Slides 
were washed three times with Tris Buffer Saline with 0.1% 
Tween-20 (TBST). Thereafter, tissue slides were incubated 
with primary antibodies (CD68,(1:100),CD163,(1:100)
(BioRad,USA), CD206 (1:100)(SantaCruz, USA), CD86 
(1:100) (BD Bioscience, USA) diluted 1:100 overnight at 
4 °C in PBS containing 0.1% Tween-20 and 0.01% triton 
X-100. Slides were further processed using EnVision™ 
detection systems (Dako, USA) following the manufac-
turer’s instructions. The slides were then counterstained 
using hematoxylin, and mounted. Images were acquired 
using Leica DM4000D (Leica, AG Germany).
RNA Isolation
Total RNA was extracted from the freshly sorted cells using 
the kit NucleoSpin® RNA (MACHEREY–NAGEL, Düren, 
Germany) according to the manufacturer‘s protocol.The con-
centration was determined using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE). RNA 
integrity was determined by assessing an aliquot of each RNA 
sample on an Agilent Bioanalyzer (Agilent Technologies, Palo 
Alto, CA).
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Microarray
Labeling was performed using the Agilent LowInput Quick-
Amp Labeling Kit One-Color (5190 − 2305; Agilent Tech-
nologies).The SurePrint G3 Rat GE 8 × 60K Kit were used 
(G4853A, Agilent Technologies). Briefly, first-strand cDNA 
synthesis was performed using an oligo(dT) 24 primer con-
taining a T7 RNA polymerase promoter site. The cDNA 
was used as a template to generate Cy3-labeled cRNA that 
was used for hybridization. After purification and fragmen-
tation, aliquots of each sample were hybridized to Agilent 
Oligo Microarrays (G2534-60014, Agilent Technologies). 
After hybridization, each array was sequentially washed and 
scanned by Agilent microarray scanner. Arrays were indi-
vidually visually inspected for hybridization defects, and 
quality control procedures were applied as recommended by 
the manufacturer of the arrays. For array readout, Agilent 
Feature Extraction 9.5.3 Software was used, and microarray 
data were imported, log2-transformed and quantile normal-
ized using robust multi-array average (RMA), and expression 
levels were summarized on a transcript level using average 
gene expression values of the replicated probes, as recently 
described [19]. Differential gene expression was calculated 
using the moderated t-test as described by Ritchie et al. [20] 
and implemented in the R/Bioconductor package limma.
Gene Set Enrichment Analysis
The results of the differential expression analysis was used 
to perform gene set enrichment analysis (GSEA) using the 
SetRank method [21]. The key principle of this algorithm 
is that it discards gene sets that have initially been flagged 
as significant, if their significance is only due to the overlap 
with another gene set. It calculates the p-value of a gene set 
using the ranking of its genes in the ordered list of p-values 
as calculated by limma and therefore does not require the 
input gene list to be divided into significant and non-sig-
nificant genes using a p-value cutoff. The following data-
bases were searched for significant gene sets: BIOCYC [22], 
Gene Ontology (GO) [23], ITFP [24], KEGG [25], Phospho-
SitePlus [26], REACTOME [27], and WikiPathways [28].
Network Analysis
For each of the significant gene sets returned by SetRank, 
all protein–protein interactions were retrieved from the 
STRING [29] database and visualized in Cytoscape [30]. 
For each edge in the resulting networks, a cost score was 
calculated as the logarithm of the geometric mean of the 
adjusted p-value of the interacting genes. This score was 
then taken into account to calculate for every node and every 
edge a betweenness value using the igraph package for R [31] 
Betweenness centrality quantifies the number of times the 
shortest paths between any two nodes passes through a given 
node. This betweenness was used to evaluate the importance 
of individual genes in a network, as described in 21.
Ashcroft Scoring and Sircol Assay for Assessment 
of Collagen
Routine hematoxylin and eosin staining was performed with 
formalin-fixed tissue sections. To evaluate the extent of pulmo-
nary fibrosis, the scoring system of Ashcroft [32] was used by a 
trained pathologist as previously reported [18]. For Sircol colla-
gen assay Lung tissue was minced and weighted and amount of 
acid soluble collagen was assessed using Sircol collagen assay 
(Biocolor Ltd, County Antrim UK) according to the manufac-
turer’s instructions. The wet weight was measured and lungs 
were snap frozen. The frozen lung was homogenized in 1x PBS 
and the homogenate was treated with Sircol dye reagent for 
30 min at room temperature. After brief centrifugation the pel-
let was dissolved in alkali reagent and was measured at 540 nm 
using Tecan M1000 plate reader (Tecan, AG Switzerland).
Statistics
The graphs were constructed and the data analyzed using 
GraphPad Prism software (GraphPad 7, San Diego, CA, 
USA). Data are shown as mean ± SEM. Statistical analysis 
was performed using a two tailed unpaired Student’s t-test. 
Differences with P values ≤ 0.05 were considered significant.
Results
Secretome of iPSC Modulates Macrophage 
Percentage in Vivo
Immunohistochemistry of formalin fixed tissue was per-
formed. Normal lung sections were stained for CD68 
(Fig. 1a), CD206 (Fig. 1d), and CD86 (Fig. 1g). Immu-
nostaining revealed increased macrophage staining in 
bleomycin injured lungs treated with control media CD68 
(Fig. 1b), CD206 (Fig. 1e), and CD86 (Fig. 1h). In con-
trast, macrophages showed reduced staining for CD68 
(Fig. 1c), CD206 (Fig. 1f), and CD86 (Fig. 1i) 7 days after 
treatment with iPSC-cm, compared to animals treated with 
control media (Fig. 1b and e).
Percentage of Macrophages is Altered After iPSC‑cm 
Treatment
Single cells isolated from lung parenchyma were stained 
for various macrophage markers and FACS analysis was 
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performed. In the normal lung 14.38 ± 1.00% of the total 
cells stained positive for CD68. In the bleomycin injured 
animals treated with control media, CD68 positive cells 
increased to 26.18 ± 1.49%, (p˂0.0006) in the lungs treated 
with iPSC-cm the number of CD68 positive cells reduced 
to 17.35 ± 0.66% (p˂0.017)(Fig.  2a). A similar trend 
was observed with specific markers of M1 and M2 mac-
rophages. In the group treated with control media the level 
of CD86 (M1 marker) increased to 32.25 ± 2.88% com-
pared to 5.8 ± 0.27% p˂0.0001 in the healthy lung. After 
iPSC-cm treatment, the number of CD86 positive cells was 
significantly reduced to 17.95 ± 4.71% p˂0.048 (Fig. 2b).
The percentage of cells positive for both the M2 mark-
ers CD163 and CD206 in healthy lung was 1.10 ± 0.19%. 
The percentage of M2 macrophages increased to 
3.20 ± 0.62% in the group treated with control media 
p˂0.003. However, in the iPSC-cm treated animals the 
percentage reduced to 1.32 ± 0.42% p˂0.04 (Fig.  2c). 
Percentage of cells expressing both the markers CD86 
and CD206 showed increase in animals treated with 
control media (42.85 ± 4.07%) compared to healthy lung 
(2.60 ± 0.39%) p˂0.173, in the iPSC-cm treated ani-
mals the percentage of double positive cells dropped to 
(24.40 ± 5.79%)p˂0.044 (Fig. 2d).
Interestingly, the percentage of CD68 positive mac-
rophages decreased over time in the treated group com-
pared to the control group, where increased number of 
macrophages were observed (Fig.  3a). Moreover, M1 
macrophages surged at 24 h in control media and a time 
dependent decline was observed over 7 days, however in 
the iPSC-cm treated group M1 macrophages showed sud-
den increase at 72 h post treatment (Fig. 3b). Interestingly, 
M2 macrophages surged at 24 h after iPSC-cm treatment, 
followed by steady decline till day 7 (Fig. 3c). Finally, 
the double positive macrophages also showed an increase 
in percentage at 24 h followed by steady decline in treat-
ment group whereas in the control group a time dependent 
increase was observed over 7 days (Fig. 3d).
Fig. 1  Immunohistochemistry on rat lungs slides from control group 
show more infiltration of macrophages in the interstitium and in 
the alveolar space (b). Positive staining for M2 cells (e) and M1 (h) 
was also found in the lung treated with control media. After iPSC-
cm treatment, lung structure was improved and less macrophages are 
seen in both the interstitium and in the alveolar space (c). Further-
more, M2 (f) and M1 (i) macrophages were also reduced. Panels a,d, 
and g show the same macrophage markers in normal rat lung
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Fig. 2  Percentage of total mac-
rophages  (CD68+) present after 
single cell isolation (a). Percent-
age of M1  (CD86+) (b) and M2 
 (CD206+) (c) macrophages. 
Percentage of macrophages pos-
itive for both M1 and M2 mark-
ers  (CD68+CD206+CD86+) (d)
Fig. 3  Time dependent effect of iPSC secretome on the percentage of interstitial macrophages (a), M1 macrophages  (CD86+) (b), M2 mac-
rophages  (CD206+) (c), M1/M2 macrophages  (CD68+CD206+CD86+) (d)
Stem Cell Reviews and Reports 
1 3
Microarray Analysis
The microarray analysis revealed upregulation of 384 genes 
(p ≤ 0.05) / 71 genes (p ≤ 0.01)/ 7 genes (p ≤ 0.001) and 
downregulation of 831 genes (p ≤ 0.05) / 298 genes (p ≤ 0.01) 
/ 75 genes (p ≤ 0.01) after treatment with the secretome of 
iPSC (Fig. 4). The raw microarray data are deposited in the 
ArrayExpress database under accession E-MTAB-5619.
Pathway Analysis
Gene Set Enrichment analysis using the SetRank algorithm 
on the differential gene expression returned the following 3 
pathways as most significant: “morphogenesis of a branching 
structure” (GO term GO:0001763), “toxoplasmosis” (KEGG 
pathway ko05145) and “regulation of canonical WNT signal-
ing pathway” (GO term GO:0060828) (Fig. 5). For each of 
these pathways, we visualized the known and predicted pro-
tein–protein interactions (PPIs), as reported by the STRING 
database [29]. We then used the betweenness centrality meas-
ure to assess the importance of each gene in a given pathway. 
Betweenness centrality of a given node N – i.e. a gene – in 
a network is defined as the number of all shortest paths con-
necting any two other nodes X and Y that pass through N.
The most significantly affected pathway is “morpho-
genesis of a branching structure” (GO term GO:0001763; 
(Fig.  6). The Src proto-oncogene (Src) and the vascu-
lar endothelial growth factor A (Vegfa) have the highest 
betweenness values in this pathway. Of these two, Vegfa is 
significantly down-regulated (adjusted p = 0.005) whereas 
the expression value of Src does not change significantly. 
This observation suggests that, in this pathway, a dominant 
role is played by VEGF-a gene. Downregulation of VEGF-
a seems to affect several other genes that are responsible 
for lung remodeling, most notably fibroblast growth fac-
tor receptor 2 (Fgfr2), which is up-regulated and Placental 
Growth Factor (Pgf), a close homolog of VEGF-a, which is 
also down-regulated. Vegfa especially supports pathological 
angiogenesis and enhances fibrosis [33].
The second pathway is referred as “toxoplasmosis” 
(KEGG pathway ko05145). Network analysis for this path-
way revealed a tight cluster of protein–protein interactions, 
indicative of a protein-complex (Fig. 7). The gene symbols 
(RT1-DOa, RT1-Da, RT1-Db1, RT1-DMa, RT1-DMb, RT1-
Ha, RT1DOb) reveal that this complex is the Major Histo-
compatibility Complex II (MHC-II). As all nodes in this 
cluster are interconnected, a betweenness-based analysis is 
not very useful. As shown by the large label sizes and red 
label color (see figure legend), almost all genes involved in 
this complex are slightly but significantly up-regulated. This 
upregulation indicates an activation of the immune response 
of the macrophages.
Fig. 4  Cumulative adjusted p-value distribution for both up- and downregulated genes in the microarray analysis (a). Volcano plot for showing 
the adjusted p-value as a function of log-fold change for the microarray analysis (b)
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The same group of MHC class II genes is also present in 
the “Tuberculosis” pathway, which was also detected as sig-
nificant by our pathway analysis as shown before in (Fig. 5).
The third pathway affected by the secretome is the “reg-
ulation of canonical WNT signaling pathway” (GO term 
GO:0060828; Fig. 8). In this pathway, betweenness values 
suggest a central role for the Axin 2 (Axin2) gene, which is 
a potent WNT inhibitor [35]. Axin2 is found to be up-regu-
lated and interacts with Apc2, another suppressor of WNT 
signalling. It has been showed that M2 macrophages acti-
vate WNT signalling pathway in epithelial cells [36]. These 
observations suggest that treatment with iPSC-cm supresses 
WNT signalling. Note that Axin2 and its interacting part-
ners are also part of the “skeletal system morphogenesis” 
pathway (Fig. 9).
iPSC Cells Maintain Pluripotency After Growing 
for 24 Hours in Starved Conditions.
The iPSC colonies were grown in media deprived of serum 
replacment and bFGF for collection of the secretome.
These colonies stained positive for markers of pluripo-
tency, in particular (Fig. 10a) Oct3/4 (Fig. 10b) Nanog 
(Fig. 10c) Sox-2 (Fig. 10d) TRA-1-60 (Fig. 10e) TRA-1-
81 (Fig. 10 f) DAPI.
iPSC‑cm Treatment Reduces Fibrosis in Bleomycin 
Injured Rat Lung
Bleomycin injured rats when treated with control media 
showed increased fibrosis (Fig. 9a), in contrast the animals 
treated with iPSC-cm showed significant improvement in 
lung architecture as shown by histology (Fig. 9b). Semi-
quantitative analysis of the histology slides by Ashcrofts 
score confirmed the observation (control media 3.93 ± 0.30 
vs iPSC-cm treated 2.4 ± 0.34) compared to healthy con-
trols: (1.74 ± 0.42) (Fig. 9c). Accordingly the level of solu-
ble collagen as measured by Sircol assay were also reduced 
in the lungs of iPSC-cm-treated animals compared with 
bleomycin animals (57.74 ± 9.3 μg/mg vs. 202 ± 29.57 μg/
mg). Collagen content of healthy lung was 10.04 ± 1.49 μg/
mg (Fig. 9d).
Fig. 5  Visualization of the most 
significant pathways as returned 
by the SetRank algorithm. Each 
column represents a pathway. 
Each dot represents a gene. 
The size of a dot reflects its 
significance. The colour of a dot 
reflects the corrected p-value of 
the entire pathway. The position 
on the vertical axis represents 
the log-fold change value
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Discussion
Intratracheal instillation of the iPSC-cm in the bleomycin 
injured rat lungs reduced fibrosis and total number of mac-
rophages. Additionally, the percentage of M1 and M2 mac-
rophages in the lung also decreased. Gene set enrichment 
analysis on the microarray data showed the involvement of 
three main groups of pathways: (a) branching morphogenesis, 
(b) immune regulation, and (c) tissue regeneration after injury.
Various cell types are involved in regulation of tissue 
repair after injury, however macrophages play critical role 
in all stages of repair and fibrosis by displaying remarkable 
flexibility for adaptation to specific stimuli [37]. The clas-
sification of macrophage subpopulations has been revised 
recently depending on their secretory and gene regulatory 
pattern [9]. However, for ease of explanation in the current 
study we used the M1(CD86+) and M2 (CD206+/CD163+) 
classification based on the surface marker expression [38]. 
In line with our previous report, significant reduction in 
collagen content and improved histology was observed 
seven days after iPSC-cm treatment in bleomycin injured 
rat lungs 16. It is suggested that M1 macrophages are pro-
inflammatory and have an antifibrotic effect [39, 40], while 
M2 macrophages are profibrotic and play a critical role in 
remodeling and fibrotic process [41].
Fig. 6  Network showing the most important gene interactions for 
the “morphogenesis of a branching structure” pathway (GO term 
GO:0001763). Interactions are retrieved from the STRING database 
[34]. The fill color of each node reflects the log-fold change of a gene 
in our microarray experiment with yellow to red indicating up-reg-
ulation and blue to cyan indicating down-regulation. The width of 
a node reflects the betweenness centrality of that node in the entire 
interactome; the height of a node reflects the betweenness only within 
this pathway. The node label color indicates how high the gene was 
ranked in the differential gene expression analysis, going from black 
to red with increasing significance. Thickness of an edge reflects the 
evidence strength for an interaction as reported by the STRING data-
base
Fig. 7  Network showing the most important gene interactions for 
the “toxoplasmosis” pathway (KEGG pathway ko05145). The gene 
upregulated are all gene of the MHC family. Interactions are retrieved 
from the STRING database [34]. The fill color of each node reflects 
the log-fold change of a gene in our microarray experiment with yel-
low to red indicating up-regulation and blue to cyan indicating down-
regulation. The width of a node reflects the betweenness centrality 
of that node in the entire interactome; the height of a node reflects 
the betweenness only within this pathway. The node label color indi-
cates how high the gene was ranked in the differential gene expres-
sion analysis, going from black to red with increasing significance. 
Thickness of an edge reflects the evidence strength for an interaction 
as reported by the STRING database
Fig. 8  Network showing the most important gene interactions for the 
“regulation of canonical WNT signaling” (GO term GO:0060828) 
pathway. Interactions are retrieved from the STRING database [34]. 
The fill color of each node reflects the log-fold change of a gene in 
our microarray experiment with yellow to red indicating up-regu-
lation and blue to cyan indicating down-regulation. The width of a 
node reflects the betweenness centrality of that node in the entire 
interactome; the height of a node reflects the betweenness only within 
this pathway. The node label color indicates how high the gene was 
ranked in the differential gene expression analysis, going from black 
to red with increasing significance. Thickness of an edge reflects the 
evidence strength for an interaction as reported by the STRING data-
base
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We observed a reduction in the total interstitial mac-
rophages after iPSC-cm treatment compared to untreated or 
animals treated with control media. More interestingly, the 
percentage of both M1 and M2 macrophages was signifi-
cantly reduced at day 7 after iPSC-cm treatment. A switch 
between M1 and M2 is suggested to be essential for resolu-
tion of inflammation, remodeling and repair and is regulated 
by various factors [41]. We, however, did not observe a shift 
in balance between the two macrophage subtypes at day 7 
after treatment in our model. To further study possible phe-
notype transition in time dependent manner, we analyzed 
the effect of iPSC-cm at different time points in bleomycin 
injured rat lungs. We did observe an increase in M1 cells 
at 48 h and 72 h after iPSC-cm treatment, which reduced 
at day 7. In contrast, the percentage of M2 cells showed a 
surge at 24 h and then a steady decline over time, suggesting 
an initial role of M1 macrophages of possibly initiating the 
repair process by stimulating inflammatory process and that 
of M2 macrophages of starting initial remodeling.
Additionally, we observed a small population of cells 
which stained positive for markers of both M1 and M2 
(CD68 + CD206 + CD86+) in bleomycin injured lungs. 
iPSC-cm treatment also reduced the percentage of this cell 
population significantly. This cell population was not detected 
in normal lung tissue. The exact role of this population and 
its possible transition could not be elucidated due to the small 
number of cells. Their expansion in vitro was not performed 
since this procedure could alter the cell characteristics and 
may therefore not represent the exact in vivo physiology. We 
speculate that these might be the cells in transition from M2 
to M1, as M1 are suggested to be antifibrotic [42].
To further evaluate the effect of iPSC-cm on global gene 
expression, interstitial macrophages were sorted from the 
lung and transcriptome analysis using gene microarrays was 
performed. As mentioned before, since the role of intersti-
tial macrophages (IMs) is not fully known [12], we focused 
our study on IMs. Transcriptome analysis of the isolated 
IMs revealed very interesting results. Three unique path-
ways were highlighted after gene set enrichment analysis 
was performed by comparing the gene expression of mac-
rophages from bleomycin injured lung treated with control 
media and those treated with the secretome of iPSC. The 
three pathways involved are (a) morphogenesis of a branch-
ing structure (b) toxoplasmosis (immune regulation) and (c) 
regulation of canonical WNT pathways.
The GO term “Morphogenesis of branching structure” was 
the most significant pathway affected. The most striking find-
ing was the downregulation of vascular endothelial growth 
factor A (VEGF-A). VEGF-A is an essential regulator of 
angiogenesis and has been implicated in pathogenesis of lung 
fibrosis, and is demonstrated to be a marker of disease sever-
ity and progression [43]. More interestingly, anti VEGF treat-
ment attenuated lung fibrosis in experimental studies [44] 
and also in clinical settings [45]. Recently, a small molecule 
Fig. 9  Haematoxylin and 
eosin staining for lungs treated 
with control media (a) and 
iPSC conditioned media (b). 
Administration of iPSC-cm to 
bleomycin-injured rat lungs 
showed significant attenuation 
of fibrosis as assessed by semi-
quantitative analysis using the 
Ashcroft score (control media 
3.93 ± 0.30 vs iPSC-cm treated 
2.4 ± 0.34), healthy controls: 
(1.74 ± 0.42) (c). In accordance, 
marked reduction in the soluble 
collagen content was detected 
in the lungs of iPSC-cm-treated 
animals compared with bleomy-
cin animals (57.74 ± 9.3 μg/mg 
vs. 202 ± 29.57 μg/mg). Colla-
gen content of healthy lung was 
10.04 ± 1.49 μg/mg (d)
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inhibitor targeting the receptor kinases (Nintedanib) has been 
approved and is now accepted in clinical application as treat-
ment for IPF [46]. Macrophages produce VEGF to support 
angiogenesis in hypoxic condition that leads to progression 
of fibrosis [47]. We observe significant down regulation of 
VEGF by macrophages in response to iPSC-cm treatment, 
suggesting that the secretome is targeting a very essential 
profibrotic pathway thus exerting antifibrotic action.
Further insight on the pathways affected by the secretome 
of iPSC revealed MHC class II activation. MHC class II are a 
set of surface proteins that are essential to recognize external 
pathogens, play an immunoregulatory role and are exclusively 
present on the antigen presenting cells. A consistent finding in 
fibrotic lungs is the presence of T cells. Indeed, complex inter-
play between T effector and T regulatory cells in lung fibrosis 
has been observed [48]. In patients with IPF both  CD4+ and 
 CD8+ positive cells have been reported, with increased  CD8+ 
positive cells indicating towards worse clinical condition [49]. 
Two broad mechanisms by which T cells might influence the 
fibrotic process include production of Th-1 or Th-2 cytokines 
[50, 51] and cell surface molecule interactions with epithe-
lial or mesenchymal cells [52, 53]. In the current study, we 
observed upregulation of MHC class II genes that negatively 
regulate T cells [54], possibly representing another antifibrotic 
mechanism of the iPSC secretome.
Furthermore, the WNT pathway was also influenced by 
the iPSC secretome. Network analysis revealed upregulation 
of Axin2. Axin2/Conductin is a negative regulator of WNT 
signalling pathway [55]. WNT signalling family proteins 
are essential for lung development and morphogenesis [56] 
and are linked to pathogenesis of pulmonary fibrosis [57]. 
Detailed microarray screenings have revealed upregulation 
of WNT genes in fibrotic lungs [58]. Interestingly, inhibition 
of WNT inducible signalling proteins reduce lung fibrosis 
in an experimental mouse model [59]. We observed upregu-
lation of Axin2, a negative regulator of WNT signalling, 
indicating that the iPSC secretome downregulates WNT sig-
nalling and possibly reducing TGFb1 via this mechanisms 
as reported in our previous study [16]. Another study by 
Cosin-Roger J et al. [36] demonstrated that M2 macrophages 
activated WNT signalling in relation to Ulcerative colitis. 
Therefore, a WNT downregulation may further explain why 
the iPSC secretome has a beneficial effect on fibrosis by act-
ing through macrophages.
In this study, we report the antifibrotic effect of iPSC 
secretome in a rat lung injury model being mediated by alter-
ing macrophage gene expression. Based on our findings, we 
Fig. 10  For collection of iPSC-cm the iPSC were grown in media depleted with serum and bFGF for 24 h to conform their pluripotency iPSC 
colonies were stained with pluripotency markers. a Oct3/4 (b) Nanog (c) Sox-2 (d) TRA-1-60 (e) TRA-1-81 (f) DAPI
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propose macrophages as potentially important therapeutic 
targets, since one subpopulation of macrophages is involved 
in the pathogenesis and progression of fibrosis, whereas 
another subpopulation of the macrophages is able to resolve 
fibrosis. Therefore, a therapeutic approach that tilts the bal-
ance towards resolving macrophages would be desirable.
To investigate this hypothesis, we performed an unbiased 
analysis by applying GSEA on an expression microarray 
dataset to get a general idea of the effects of iPSC secretome 
on the IMs gene expression in bleomycin injured rat lung. 
A limitation of using a rat model is that it is difficult to get 
a precise mechanistic insight into which human iPSC pro-
teins are binding or affecting which rat macrophage proteins 
and genes. Indeed, none of the currently publicly available 
protein interaction databases contains an extensive list of 
protein–protein interactions between proteins from these 
two species. We deliberately did not attempt to first map the 
iPSC proteins to their rat orthologs, as it has been shown 
repeatedly that gene signaling and regulatory networks are 
highly divergent between mammalian species, even though 
the sequences of the proteins involved might be relatively 
well conserved [60]. Another limitation of our study is that 
we did not evaluate the effect of iPSC-cm at very early time 
points i.e. before 24 h after instillation.
Despite these limitations, our pathway analysis does 
identify several candidate pathways affected by treatment 
with iPSC medium. Performing in vitro studies on the cells 
obtained from humans might supplement our findings. Our 
data indicates that antifibrotic role of iPSC secretome in part 
is due to its effect on interstitial macrophage in bleomycin 
injured rat lung. This is the first of its kind of study utilizing 
network analysis to identify global changes in macrophage 
genome under influence of iPSC secreteome. More detailed 
analysis is however required to understand the precise mecha-
nisms of iPSC secretome to further consolidate its use as a 
potential antifibrotic agent.
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